TY - JOUR
T1 - Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation
T2 - Retrospective feasibility study on six cases
AU - Vavassori, Andrea
AU - Jereczek-Fossa, Barbara Alicja
AU - Beltramo, Giancarlo
AU - De Cicco, Luigi
AU - Fariselli, Laura
AU - Bianchi, Livia Corinna
AU - Possanzini, Marco
AU - Bergantin, Achille
AU - DeCobelli, Ottavio
AU - Orecchia, Roberto
PY - 2010/1
Y1 - 2010/1
N2 - Aims and background. Technological advances in treatment planning and execution are providing new potential opportunities in the treatment of recurrent prostate cancer. This studywas conducted to evaluate the feasibility and safety of reirradiationwith image-guided radiosurgery using CyberKnife, a robotic arm-driven compact linear accelerator, for intraprostatic recurrence after external beam radiotherapy (EBRT). Methods. Between September 2007 and May 2008, 6 patients diagnosed with locally recurrent prostate cancer after EBRT were treated using the CyberKnife system. The total reirradiation dose was 30 Gy in five fractions. Prior to radiosurgery four patients were treated with androgen-deprivation therapy. Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria and the Houston-Phoenix definition (PSA nadir + 2 ng/mL) were used for toxicity and biochemical failure evaluation, respectively. Results. After a median follow-up of 11.2 months (range, 9.6-18.6 months), all patients are alive with no evidence of severe urinary or rectal acute morbidity. Local control cannot be exactly determined due to the short follow-up and the bias of the use of androgen ablation. Four patients had biochemical failure, three of them with clinical failure evidence (lymph node, bone and lung metastasis, respectively): none of these patients had clinical evidence of tumor persistence in the prostate. Conclusions. Salvage radiosurgery with CyberKnife after irradiation is feasible with low urinary and rectal morbidity. A longer follow-up and a larger number of patients are necessary to evaluate its effectiveness and optimal patient selection criteria. Free full text available at www.tumorionline.it.
AB - Aims and background. Technological advances in treatment planning and execution are providing new potential opportunities in the treatment of recurrent prostate cancer. This studywas conducted to evaluate the feasibility and safety of reirradiationwith image-guided radiosurgery using CyberKnife, a robotic arm-driven compact linear accelerator, for intraprostatic recurrence after external beam radiotherapy (EBRT). Methods. Between September 2007 and May 2008, 6 patients diagnosed with locally recurrent prostate cancer after EBRT were treated using the CyberKnife system. The total reirradiation dose was 30 Gy in five fractions. Prior to radiosurgery four patients were treated with androgen-deprivation therapy. Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria and the Houston-Phoenix definition (PSA nadir + 2 ng/mL) were used for toxicity and biochemical failure evaluation, respectively. Results. After a median follow-up of 11.2 months (range, 9.6-18.6 months), all patients are alive with no evidence of severe urinary or rectal acute morbidity. Local control cannot be exactly determined due to the short follow-up and the bias of the use of androgen ablation. Four patients had biochemical failure, three of them with clinical failure evidence (lymph node, bone and lung metastasis, respectively): none of these patients had clinical evidence of tumor persistence in the prostate. Conclusions. Salvage radiosurgery with CyberKnife after irradiation is feasible with low urinary and rectal morbidity. A longer follow-up and a larger number of patients are necessary to evaluate its effectiveness and optimal patient selection criteria. Free full text available at www.tumorionline.it.
KW - CyberKnife
KW - Prostate cancer
KW - Reirradiation
KW - Salvage therapy
UR - http://www.scopus.com/inward/record.url?scp=77950793999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950793999&partnerID=8YFLogxK
U2 - 10.1700/479.5654
DO - 10.1700/479.5654
M3 - Article
C2 - 20437861
AN - SCOPUS:77950793999
SN - 0300-8916
VL - 96
SP - 71
EP - 75
JO - Tumori
JF - Tumori
IS - 1
ER -